Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 312.4 g/mol |
---|---|
Molecular Formula | C17H20N4S |
XLogP3 | 2.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 1 |
Exact Mass | 312.14086783 g/mol |
Monoisotopic Mass | 312.14086783 g/mol |
Topological Polar Surface Area | 56.2 A^2 |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 543 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 8 | |
---|---|
Drug Name | Olanzapine |
PubMed Health | Olanzapine |
Drug Classes | Antipsychotic |
Drug Label | Olanzapine is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresponds to a... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet; Injectable; Tablet, orally disintegrating |
Route | oral; Oral; Intramuscular |
Strength | 2.5mg; 10mg/vial; 7.5mg; 15mg; 5mg; 10mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharms; Apotex; Aurobindo Pharma; Sun Pharm Inds; Torrent Pharms; Barr Labs; Sandoz; Par Pharm; Roxane; Teva Pharms; Macleods Pharms; Jubilant Generics; Luitpold; Dr Reddys Labs; Orchid Hlthcare; Mylan |
2 of 8 | |
---|---|
Drug Name | Symbyax |
PubMed Health | Olanzapine/Fluoxetine (By mouth) |
Drug Classes | Antidepressant, Antipsychotic |
Active Ingredient | Fluoxetine hydrochloride; olanzapine |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg base; eq 6mg base; eq 12mg base; eq 3mg base; eq 25mg base |
Market Status | Prescription |
Company | Lilly |
3 of 8 | |
---|---|
Drug Name | Zyprexa |
Drug Label | ZYPREXA (olanzapine) is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresp... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet; Injectable |
Route | Oral; Intramuscular |
Strength | 2.5mg; 10mg/vial; 7.5mg; 15mg; 5mg; 10mg; 20mg |
Market Status | Prescription |
Company | Lilly |
4 of 8 | |
---|---|
Drug Name | Zyprexa zydis |
Drug Label | ZYPREXA (olanzapine) is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresp... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet, orally disintegrating |
Route | Oral |
Strength | 15mg; 5mg; 10mg; 20mg |
Market Status | Prescription |
Company | Lilly |
5 of 8 | |
---|---|
Drug Name | Olanzapine |
PubMed Health | Olanzapine |
Drug Classes | Antipsychotic |
Drug Label | Olanzapine is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresponds to a... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet; Injectable; Tablet, orally disintegrating |
Route | oral; Oral; Intramuscular |
Strength | 2.5mg; 10mg/vial; 7.5mg; 15mg; 5mg; 10mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharms; Apotex; Aurobindo Pharma; Sun Pharm Inds; Torrent Pharms; Barr Labs; Sandoz; Par Pharm; Roxane; Teva Pharms; Macleods Pharms; Jubilant Generics; Luitpold; Dr Reddys Labs; Orchid Hlthcare; Mylan |
6 of 8 | |
---|---|
Drug Name | Symbyax |
PubMed Health | Olanzapine/Fluoxetine (By mouth) |
Drug Classes | Antidepressant, Antipsychotic |
Active Ingredient | Fluoxetine hydrochloride; olanzapine |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg base; eq 6mg base; eq 12mg base; eq 3mg base; eq 25mg base |
Market Status | Prescription |
Company | Lilly |
7 of 8 | |
---|---|
Drug Name | Zyprexa |
Drug Label | ZYPREXA (olanzapine) is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresp... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet; Injectable |
Route | Oral; Intramuscular |
Strength | 2.5mg; 10mg/vial; 7.5mg; 15mg; 5mg; 10mg; 20mg |
Market Status | Prescription |
Company | Lilly |
8 of 8 | |
---|---|
Drug Name | Zyprexa zydis |
Drug Label | ZYPREXA (olanzapine) is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresp... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet, orally disintegrating |
Route | Oral |
Strength | 15mg; 5mg; 10mg; 20mg |
Market Status | Prescription |
Company | Lilly |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
68
PharmaCompass offers a list of Olanzapine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Olanzapine manufacturer or Olanzapine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Olanzapine manufacturer or Olanzapine supplier.
PharmaCompass also assists you with knowing the Olanzapine API Price utilized in the formulation of products. Olanzapine API Price is not always fixed or binding as the Olanzapine Price is obtained through a variety of data sources. The Olanzapine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A ZYPREXA RELPREVV manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ZYPREXA RELPREVV, including repackagers and relabelers. The FDA regulates ZYPREXA RELPREVV manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ZYPREXA RELPREVV API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of ZYPREXA RELPREVV manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A ZYPREXA RELPREVV supplier is an individual or a company that provides ZYPREXA RELPREVV active pharmaceutical ingredient (API) or ZYPREXA RELPREVV finished formulations upon request. The ZYPREXA RELPREVV suppliers may include ZYPREXA RELPREVV API manufacturers, exporters, distributors and traders.
click here to find a list of ZYPREXA RELPREVV suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A ZYPREXA RELPREVV DMF (Drug Master File) is a document detailing the whole manufacturing process of ZYPREXA RELPREVV active pharmaceutical ingredient (API) in detail. Different forms of ZYPREXA RELPREVV DMFs exist exist since differing nations have different regulations, such as ZYPREXA RELPREVV USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A ZYPREXA RELPREVV DMF submitted to regulatory agencies in the US is known as a USDMF. ZYPREXA RELPREVV USDMF includes data on ZYPREXA RELPREVV's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ZYPREXA RELPREVV USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of ZYPREXA RELPREVV suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The ZYPREXA RELPREVV Drug Master File in Japan (ZYPREXA RELPREVV JDMF) empowers ZYPREXA RELPREVV API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the ZYPREXA RELPREVV JDMF during the approval evaluation for pharmaceutical products. At the time of ZYPREXA RELPREVV JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of ZYPREXA RELPREVV suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a ZYPREXA RELPREVV Drug Master File in Korea (ZYPREXA RELPREVV KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of ZYPREXA RELPREVV. The MFDS reviews the ZYPREXA RELPREVV KDMF as part of the drug registration process and uses the information provided in the ZYPREXA RELPREVV KDMF to evaluate the safety and efficacy of the drug.
After submitting a ZYPREXA RELPREVV KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their ZYPREXA RELPREVV API can apply through the Korea Drug Master File (KDMF).
click here to find a list of ZYPREXA RELPREVV suppliers with KDMF on PharmaCompass.
A ZYPREXA RELPREVV CEP of the European Pharmacopoeia monograph is often referred to as a ZYPREXA RELPREVV Certificate of Suitability (COS). The purpose of a ZYPREXA RELPREVV CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of ZYPREXA RELPREVV EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of ZYPREXA RELPREVV to their clients by showing that a ZYPREXA RELPREVV CEP has been issued for it. The manufacturer submits a ZYPREXA RELPREVV CEP (COS) as part of the market authorization procedure, and it takes on the role of a ZYPREXA RELPREVV CEP holder for the record. Additionally, the data presented in the ZYPREXA RELPREVV CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the ZYPREXA RELPREVV DMF.
A ZYPREXA RELPREVV CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. ZYPREXA RELPREVV CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of ZYPREXA RELPREVV suppliers with CEP (COS) on PharmaCompass.
A ZYPREXA RELPREVV written confirmation (ZYPREXA RELPREVV WC) is an official document issued by a regulatory agency to a ZYPREXA RELPREVV manufacturer, verifying that the manufacturing facility of a ZYPREXA RELPREVV active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting ZYPREXA RELPREVV APIs or ZYPREXA RELPREVV finished pharmaceutical products to another nation, regulatory agencies frequently require a ZYPREXA RELPREVV WC (written confirmation) as part of the regulatory process.
click here to find a list of ZYPREXA RELPREVV suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ZYPREXA RELPREVV as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for ZYPREXA RELPREVV API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture ZYPREXA RELPREVV as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain ZYPREXA RELPREVV and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ZYPREXA RELPREVV NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of ZYPREXA RELPREVV suppliers with NDC on PharmaCompass.
ZYPREXA RELPREVV Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ZYPREXA RELPREVV GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ZYPREXA RELPREVV GMP manufacturer or ZYPREXA RELPREVV GMP API supplier for your needs.
A ZYPREXA RELPREVV CoA (Certificate of Analysis) is a formal document that attests to ZYPREXA RELPREVV's compliance with ZYPREXA RELPREVV specifications and serves as a tool for batch-level quality control.
ZYPREXA RELPREVV CoA mostly includes findings from lab analyses of a specific batch. For each ZYPREXA RELPREVV CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ZYPREXA RELPREVV may be tested according to a variety of international standards, such as European Pharmacopoeia (ZYPREXA RELPREVV EP), ZYPREXA RELPREVV JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ZYPREXA RELPREVV USP).